시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 라세카도트릴(Racecadotril) 시장 보고서(2025년)
Racecadotril Global Market Report 2025
상품코드 : 1769728
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,272,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,065,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,859,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

라세카도트릴 시장 규모는 향후 수년간 강력한 성장이 전망될 예정입니다. 이러한 예상 성장은 글로벌 관광의 급증, 의료 서비스에 대한 광범위한 접근성, 고령화 인구 증가, 면역력이 저하된 환자의 설사 사례 증가, 일반의약품 이용으로의 전환으로 인한 것입니다. 예측기간 중에 예상되는 주요 동향으로는 제제의 개량, 디지털 헬스케어 툴의 통합, 바이오테크놀러지의 진보, 마이크로바이옴을 표적으로 한 솔루션, 보다 정확한 전달 메커니즘의 개발 등이 있습니다.

설사 발생률이 증가함에 따라 향후 몇 년간의 라세카도트릴 시장의 성장이 촉진될 것으로 예측됩니다. 깨끗한 식수에 대한 접근 제한으로 인해, 이들은 질병을 일으키는 병원체의 확산을 촉진합니다. 예를 들어, 2024년 3월, 스위스에 본부를 둔 유엔 전문 기관인 세계보건기구(WHO)는 설사성 질환은 연간 약 17억 건을 차지하며, 5세 미만의 소아에서는 약 44만 3,832명이 사망하고, 5세에서 9세 사이 소아에서는 약 5만 851명이 사망하고 있다고 보고했습니다.

건강 관리 지출 증가는 라세카도트릴 시장의 성장에 기여하고 있습니다. 급성 설사증과 같은 증상에 대한 효과적인 치료법에 대한 접근을 용이하게 함으로써 라세카도트릴의 사용을 지지하고 있습니다. 예를 들어 2024년 12월 미국을 거점으로 하는 연방기관인 메디케어 메디케이드 서비스센터(CMS)는 2023년 국민의료비가 7.5% 증가한 4조 9,000억 달러에 달했으며, 국내총생산(GDP) 의 17.6%를 차지했다고 보고했습니다. 2023년에서 2032년 사이에 이러한 지출은 연평균 5.6%의 비율로 증가하고, GDP에 차지하는 의료비의 비율은 2022년의 17.3%에서 2032년에는 19.7%로 증가할 것으로 예측되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

SHW
영문 목차

영문목차

Racecadotril is an antidiarrheal drug mainly prescribed for the treatment of acute diarrhea in both adults and children. It acts by blocking the enzyme enkephalinase, which helps preserve endogenous enkephalins in the intestines. This mechanism reduces the secretion of water and electrolytes into the intestinal lumen without impacting gut motility, offering symptom relief without inducing constipation.

Racecadotril is available in several product forms, including oral formulations, injectable solutions, and topical applications. Oral formulations of racecadotril-such as capsules, granules, or sachets-are administered orally to manage acute diarrhea by limiting intestinal fluid loss without altering intestinal movement. These formulations are suitable for different age demographics, including children, adults, and the elderly. The drug is used in various indications such as acute diarrhea, traveler's diarrhea, and chronic diarrhea, and it is distributed through multiple channels including retail pharmacies, hospital-based pharmacies, and online platforms. Key end-users include hospitals, clinics, and home healthcare environments.

The racecadotril market research report is one of a series of new reports from The Business Research Company that provides racecadotril market statistics, including the racecadotril industry global market size, regional shares, competitors with the racecadotril market share, detailed racecadotril market segments, market trends, and opportunities, and any further data you may need to thrive in the racecadotril industry. This racecadotril market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The racecadotril market size has grown strongly in recent years. It will grow from $3.19 billion in 2024 to $3.43 billion in 2025 at a compound annual growth rate (CAGR) of 7.7%. This growth during the historical period was driven by a higher occurrence of acute diarrhea, increased public awareness of gastrointestinal conditions, rapid urban development, widespread adoption of oral rehydration therapies, and supportive government policies aimed at managing diarrheal diseases.

The racecadotril market size is expected to see strong growth in the next few years. It will grow to $4.57 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. This projected growth is due to a surge in global tourism, broader access to medical services, a rise in the aging population, increasing diarrhea cases in immunocompromised patients, and a greater shift towards over-the-counter product availability. Key trends anticipated during the forecast period include improved formulations, the integration of digital healthcare tools, advancements in biotechnology, solutions targeting the microbiome, and the development of more precise delivery mechanisms.

The increasing incidence of diarrhea is expected to drive the growth of the racecadotril market in the coming years. Diarrhea is a condition characterized by frequent, loose, or watery bowel movements, usually occurring three or more times per day. The rise in diarrhea cases is mainly attributed to poor sanitation and limited access to clean drinking water, which facilitate the spread of disease-causing pathogens. Racecadotril is effective in treating diarrhea by decreasing excessive fluid secretion in the intestines, which helps manage acute symptoms while preserving normal bowel movements. This leads to rapid symptom relief, enhancing patient comfort and treatment outcomes. For example, in March 2024, the World Health Organization (WHO), a specialized agency of the United Nations based in Switzerland, reported that diarrheal diseases account for approximately 1.7 billion cases annually and cause around 443,832 deaths in children under the age of 5, along with an additional 50,851 deaths among children aged 5 to 9. As a result, the increasing incidence of acute diarrhea is boosting the demand for racecadotril.

The rise in healthcare expenditures is also contributing to the growth of the racecadotril market. Healthcare expenditure refers to the overall spending on medical services, treatments, facilities, research, and public health efforts aimed at maintaining or improving health outcomes. This increase is driven largely by the aging population, which requires more frequent and prolonged medical care and treatment. Greater healthcare spending supports the use of racecadotril by facilitating access to effective treatments for conditions such as acute diarrhea. It offers a cost-effective solution that reduces symptom duration and severity, thereby improving patient outcomes and easing the financial strain on healthcare systems. For instance, in December 2024, the Centers for Medicare and Medicaid Services (CMS), a U.S.-based federal agency, reported that national health expenditures rose by 7.5% to $4.9 trillion in 2023, making up 17.6% of the gross domestic product (GDP). Moreover, between 2023 and 2032, these expenditures are projected to grow at an average annual rate of 5.6%, increasing the share of health spending in GDP from 17.3% in 2022 to 19.7% by 2032. Thus, rising healthcare expenditures are playing a significant role in fueling the racecadotril market.

Companies in the racecadotril market are increasingly focusing on developing innovative formulations such as combination therapies to enhance treatment effectiveness, expand therapeutic use, and address complex or resistant cases of acute diarrhea. Combination therapy involves the simultaneous use of two or more medications to treat a single condition more effectively than a single drug alone. For instance, in April 2024, Daksh Pharmaceuticals Pvt. Ltd., an India-based pharmaceutical company, introduced the ZOFLO-R tablet, which combines ofloxacin 200 mg and racecadotril 100 mg. This dual-action formulation is designed to treat acute diarrhea of bacterial origin by offering both antimicrobial activity and symptomatic relief. Ofloxacin works by inhibiting bacterial DNA gyrase, leading to bacterial cell death, while racecadotril reduces intestinal fluid secretion to control diarrhea. Together, these actions provide comprehensive treatment for diarrhea and its associated symptoms.

Major players in the racecadotril market are Torrent Pharmaceuticals Ltd., Taj Pharma, ChemScene, Gnova Biotech, Novalab Gynecare, Jabs Biotech, Jigs Chemical, Manus Aktteva Biopharma LLP, Wellona Pharma, Biofield Pharma, Cleanchem Laboratories, Enomark, Chemcopia, Anant Pharmaceuticals Pvt. Ltd., Daffohils Laboratories, AR Life Sciences, Novagen Healthcare Pvt Ltd, Omicron Pharma, Cixmech Pharmaceuticals, and Sakthi healthcare.

North America was the largest region in the racecadotril market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in racecadotril report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the racecadotril market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The racecadotril market consists of sales of active pharmaceutical ingredients (APIs), granules, combination products, and powders for oral suspension. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Racecadotril Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on racecadotril market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for racecadotril ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The racecadotril market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Racecadotril Market Characteristics

3. Racecadotril Market Trends And Strategies

4. Racecadotril Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Racecadotril Growth Analysis And Strategic Analysis Framework

6. Racecadotril Market Segmentation

7. Racecadotril Market Regional And Country Analysis

8. Asia-Pacific Racecadotril Market

9. China Racecadotril Market

10. India Racecadotril Market

11. Japan Racecadotril Market

12. Australia Racecadotril Market

13. Indonesia Racecadotril Market

14. South Korea Racecadotril Market

15. Western Europe Racecadotril Market

16. UK Racecadotril Market

17. Germany Racecadotril Market

18. France Racecadotril Market

19. Italy Racecadotril Market

20. Spain Racecadotril Market

21. Eastern Europe Racecadotril Market

22. Russia Racecadotril Market

23. North America Racecadotril Market

24. USA Racecadotril Market

25. Canada Racecadotril Market

26. South America Racecadotril Market

27. Brazil Racecadotril Market

28. Middle East Racecadotril Market

29. Africa Racecadotril Market

30. Racecadotril Market Competitive Landscape And Company Profiles

31. Racecadotril Market Other Major And Innovative Companies

32. Global Racecadotril Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Racecadotril Market

34. Recent Developments In The Racecadotril Market

35. Racecadotril Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기